236 related articles for article (PubMed ID: 16406853)
1. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
Xu D; Lu Q; Hu X
Cancer Lett; 2006 Nov; 243(2):274-80. PubMed ID: 16406853
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
4. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
5. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
9. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
10. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
12. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
Shi R; Li W; Zhang X; Zhang Y; Peng H; Xie Y; Fan D; Liu R; Liu X; Xiong D
Eur J Pharmacol; 2011 Nov; 669(1-3):38-44. PubMed ID: 21871878
[TBL] [Abstract][Full Text] [Related]
13. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro.
Gao A; Liang H; Wang X; Zhang X; Jing M; Zhang J; Yan Y; Xiang W
Eur J Pharmacol; 2011 Jun; 659(2-3):108-13. PubMed ID: 21458446
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
15. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Li C; Guan X; Xue H; Wang P; Wang M; Gai X
Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
[TBL] [Abstract][Full Text] [Related]
16. Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis.
Han HK; Van Anh LT
Anticancer Res; 2012 Oct; 32(10):4445-52. PubMed ID: 23060571
[TBL] [Abstract][Full Text] [Related]
17. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.
Wang G; Rong J; Zhou Z; Duo J
Mol Biol (Mosk); 2010; 44(6):1010-7. PubMed ID: 21287809
[TBL] [Abstract][Full Text] [Related]
18. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
Bhat UG; Winter MA; Pearce HL; Beck WT
Mol Pharmacol; 1995 Oct; 48(4):682-9. PubMed ID: 7476894
[TBL] [Abstract][Full Text] [Related]
19. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
Chen F; Wang T; Wang J; Wang ZQ; Qian M
Acta Pharmacol Sin; 2008 Apr; 29(4):458-64. PubMed ID: 18358092
[TBL] [Abstract][Full Text] [Related]
20. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]